Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01336738 · ClinicalTrials.gov registry record · Phase 2

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

A Phase 2 study of Diabetes Type 2, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
266
Enrollment target
20
Study locations

NCT01336738 is a Phase 2 study of Diabetes Type 2 that has completed, run by Pfizer. The registered enrollment target is 266 participants, below the 730-participant average among 21 other Diabetes Type 2 trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01336738, a Phase 2 study of Diabetes Type 2, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
266 participants
Enrollment target
20
Study locations

Study Summary

B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.

Conditions Studied

Diabetes Type 2

Interventions

  • DRUG Placebo
  • DRUG 150 mg PF-04991532
  • DRUG 450 mg PF-04991532
  • DRUG 750 mg PF-04991532
  • DRUG Sitagliptin 100 mg

Study Locations (20)

Florida

  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - Melbourne
  • Pfizer Investigational Site - West Palm Beach

Arkansas

  • Pfizer Investigational Site - Jonesboro
  • Pfizer Investigational Site - Jonesboro

California

  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Palm Springs

North Carolina

  • Pfizer Investigational Site - Cary
  • Pfizer Investigational Site - Wilmington

Rhode Island

  • Pfizer Investigational Site - East Providence
  • Pfizer Investigational Site - East Providence

Tennessee

  • Pfizer Investigational Site - Bristol
  • Pfizer Investigational Site - Kingsport

Georgia

  • Pfizer Investigational Site - Conyers

Illinois

  • Pfizer Investigational Site - Chicago

Trial Details

FieldValue
Enrollment Target 266 participants
Start Date 2011-06
Est. Completion 2012-03
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01336738

The ClinicalTrials.gov registry entry for NCT01336738 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 266 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 730-participant average among 21 other Diabetes Type 2 trials with a reported enrollment target (64% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Type 2 appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT01336738 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Arkansas, California.

Frequently Asked Questions

What is clinical trial NCT01336738 about?

NCT01336738 is a clinical study titled "Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus". B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be pl...

What is the current status of trial NCT01336738?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 266 participants. The study started on 2011-06. Estimated completion is 2012-03.

What conditions does trial NCT01336738 study?

This clinical trial studies the following conditions: Diabetes Type 2.

What interventions are being tested in trial NCT01336738?

The interventions under investigation include: Placebo (DRUG), 150 mg PF-04991532 (DRUG), 450 mg PF-04991532 (DRUG), 750 mg PF-04991532 (DRUG), Sitagliptin 100 mg (DRUG).

Who is sponsoring clinical trial NCT01336738?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01336738 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Type 2

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.